In a recent prospective study, ARNi was shown to be safe and effective in patients with CTRCD thanks to previous chemotherapy for breast cancer (mainly anthracyclines and anti–human epidermal growth factor receptor 2 (HER2) treatment) [9]. The gene discussed is ERBB2; the disease is breast carcinoma.